secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001600620-26-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q4 revenue up 29% to $77.1M, EPS $1.53; guides 2026 LUPKYNIS sales $305M-$315M
--------------------------------------------------------------------------------

- LUPKYNIS net product sales for FY 2025: $271.3M, up 25% YoY; Q4 $74.2M, up 29%.
- Net income for FY 2025: $287.2M ($2.07 diluted EPS) vs $5.8M ($0.04) in 2024; includes $173.0M tax benefit.
- Cash, equivalents, restricted cash & investments: $398.0M at Dec 31, 2025; generated $135.7M from operations.
- 2026 guidance: total revenue $315M-$325M; LUPKYNIS net sales $305M-$315M (12-16% growth).
- Initiated clinical study of aritinercept (BAFF/APRIL inhibitor); plan another autoimmune study in H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/0001600620-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/auph-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001600620-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer